The RNA aptamer inhibiting human vesicular endothelial growth factor receptor 1 without affecting cytokine binding

Biochemistry

Volumn 52, Issue 13, 2013, Pages 2274-2279

  Ohuchi, Shoji P ^a   Shibuya, Masabumi ^b   Nakamura, Yoshikazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JOBU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHOSPHORYLATION; BINDING STUDIES; ENDOTHELIAL GROWTH FACTOR; INHIBITORY CONCENTRATION; SIGNALING PATHWAYS; SOLUBLE RECEPTOR; SURFACE PLASMONS; VESSEL FORMATION;

BLOOD VESSELS; NUCLEOTIDES;

RNA;

APTAMER; CYTOKINE; NUCLEOTIDE; RNA APTAMER; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1;

ARTICLE; BINDING AFFINITY; CELL STRAIN 3T3; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DRUG MECHANISM; IC 50; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; RNA SEQUENCE;

APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CYTOKINES; HEPARIN; HUMANS; INHIBITORY CONCENTRATION 50; MUTATION; PROTEIN BINDING; SELEX APTAMER TECHNIQUE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84875797681     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi301669p     Document Type: Article

References (39)

1. Lohela, M., Bry, M., Tammela, T., and Alitalo, K. (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis Curr. Opin. Cell Biol. 21, 154-165
2. Takahashi, H. and Shibuya, M. (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions Clin. Sci. 109, 227-241
3. Shibuya, M. and Claesson-Welsh, L. (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis Exp. Cell Res. 312, 549-560
4. Fong, G. H., Rossant, J., Gertsenstein, M., and Breitman, M. L. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium Nature 376, 66-70
5. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., and Shibuya, M. (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice Proc. Natl. Acad. Sci. U.S.A. 95, 9349-9354
6. Ferrara, N. (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis Am. J. Physiol. 280, C1358-C1366
7. Hattori, K., Heissig, B., Wu, Y., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Bohlen, P., Witte, L., Hendrikx, J., Hackett, N. R., Crystal, R. G., Moore, M. A., Werb, Z., Lyden, D., and Rafii, S. (2002) Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment Nat. Med. 8, 841-849
8. LeCouter, J., Moritz, D. R., Li, B., Phillips, G. L., Liang, X. H., Gerber, H. P., Hillan, K. J., and Ferrara, N. (2003) Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1 Science 299, 890-893
9. Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., Scholz, D., Acker, T., DiPalma, T., Dewerchin, M., Noel, A., Stalmans, I., Barra, A., Blacher, S., Vanden-driessche, T., Ponten, A., Eriksson, U., Plate, K. H., Foidart, J. M., Schaper, W., Charnock-Jones, D. S., Hicklin, D. J., Herbert, J. M., Collen, D., and Persico, M. G. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions Nat. Med. 7, 575-583
10. Luttun, A., Brusselmans, K., Fukao, H., Tjwa, M., Ueshima, S., Herbert, J. M., Matsuo, O., Collen, D., Carmeliet, P., and Moons, L. (2002) Loss of placental growth factor protects mice against vascular permeability in pathological conditions Biochem. Biophys. Res. Commun. 295, 428-434
11. Fischer, C., Mazzone, M., Jonckx, B., and Carmeliet, P. (2008) FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy? Nat. Rev. Cancer 8, 942-956
12. Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., Nagy, J. A., Hooper, A., Priller, J., De Klerck, B., Compernolle, V., Daci, E., Bohlen, P., Dewerchin, M., Herber, J. M., Fava, R., Matthys, P., Carmeliet, G., Collen, D., Dvorak, H. F., Hicklin, D. J., and Carmeliet, P. (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 Nat. Med. 8, 831-840
13. Pavco, P. A., Bouhana, K. S., Gallegos, A. M., Agrawal, A., Blanchard, K. S., Grimm, S. L., Jensen, K. L., Andrews, L. E., Wincott, F. E., Pitot, P. A., Tressler, R. J., Cushman, C., Reynolds, M. A., and Parry, T. J. (2000) Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors Clin. Cancer Res. 6, 2094-2103
14. Kobayashi, H., Eckhardt, S. G., Lockridge, J. A., Rothenberg, M. L., Sandler, A. B., O'Bryant, C. L., Cooper, W., Holden, S. N., Aitchison, R. D., Usman, N., Wolin, M., and Basche, M. L. (2005) Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors Cancer Chemother. Pharmacol. 56, 329-336
15. Weng, D. E., Masci, P. A., Radka, S. F., Jackson, T. E., Weiss, P. A., Ganapathi, R., Elson, P. J., Capra, W. B., Parker, V. P., Lockridge, J. A., Cowens, J. W., Usman, N., and Borden, E. C. (2005) A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors Mol. Cancer Ther. 4, 948-955
16. Shen, J., Samul, R., Silva, R. L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S. F., Zinnen, S., Kossen, K., Fosnaugh, K., Vargeese, C., Gomez, A., Bouhana, K., Aitchison, R., Pavco, P., and Campochiaro, P. A. (2006) Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1 Gene Ther. 13, 225-234
17. Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J., Yamasaki, S., Itaya, M., Pan, Y., Appukuttan, B., Gibbs, D., Yang, Z., Karikó, K., Ambati, B. K., Wilgus, T. A., DiPietro, L. A., Sakurai, E., Zhang, K., Smith, J. R., Taylor, E. W., and Ambati, J. (2008) Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 Nature 452, 591-597
18. Joyce, G. F. (2007) Forty years of in vitro evolution Angew. Chem., Int. Ed. 46, 6420-6436
19. Ellington, A. and Szostak, J. W. (1990) In vitro selection of RNA molecules that bind specific ligands Nature 346, 818-822
20. Tuerk, C. and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249, 505-510
21. Klussmann, S. (2006) The Aptamer Handbook: Functional Oligonucleotides and Their Applications, Wiley-VCH, Weinheim, Germany.
22. Ohuchi, S. P., Ohtsu, T., and Nakamura, Y. (2006) Selection of RNA aptamers against recombinant transforming growth factor-β type III receptor displayed on cell surface Biochimie 88, 897-904
23. Miyakawa, S., Nomura, Y., Sakamoto, T., Yamaguchi, Y., Kato, K., Yamazaki, S., and Nakamura, Y. (2008) Structural and molecular basis for hyperspecificity of RNA aptamer to human immunoglobulin G RNA 14, 1154-1163
24. Iwagawa, T., Ohuchi, S. P., Watanabe, S., and Nakamura, Y. (2012) Selection of RNA aptamers against mouse embryonic stem cells Biochimie 94, 250-257
25. Kobayashi, S., Sawano, A., Nojima, Y., Shibuya, M., and Maru, Y. (2004) The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1) FASEB J. 18, 929-931
26. Takahashi, T. and Shibuya, M. (1997) The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts Oncogene 14, 2079-2089
27. Pieken, W., Olsen, D., Benseler, F., Aurup, H., and Eckstein, F. (1991) Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes Science 253, 314-317
28. Zuker, M. (2003) Mfold web server for nucleic acid folding and hybridization prediction Nucleic Acids Res. 31, 3406-3415
29. Zhai, G., Iskandar, M., Barilla, K., and Romaniuk, P. (2001) Characterization of RNA aptamer binding by the Wilms' tumor suppressor protein WT1 Biochemistry 40, 2032-2040
30. Boese, B. and Breaker, R. (2007) In vitro selection and characterization of cellulose-binding DNA aptamers Nucleic Acids Res. 35, 6378-6388
31. Skrisovska, L., Bourgeois, C., Stefl, R., Grellscheid, S., Kister, L., Wenter, P., Elliott, D., Stevenin, J., and Allain, F. (2007) The testis-specific human protein RBMY recognizes RNA through a novel mode of interaction EMBO Rep. 8, 372-379
32. Goers, E., Voelker, R., Gates, D., and Berglund, J. (2008) RNA binding specificity of Drosophila muscleblind Biochemistry 47, 7284-7294
33. Ito, N. and Claesson-Welsh, L. (1999) Dual effects of heparin on VEGF binding to VEGF receptor-1 and transduction of biological responses Angiogenesis 3, 159-166
34. Park, M. and Lee, S. T. (1999) The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site Biochem. Biophys. Res. Commun. 264, 730-734
35. Lee, J. H., Canny, M. D., De Erkenez, A., Krilleke, D., Ng, Y. S., Shima, D. T., Pardi, A., and Jucker, F. (2005) A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165 Proc. Natl. Acad. Sci. U.S.A. 102, 18902-18907
36. Jeter, M. L., Ly, L. V., Fortenberry, Y. M., Whinna, H. C., White, R. R., Rusconi, C. P., Sullenger, B. A., and Church, F. C. (2004) RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins FEBS Lett. 568, 10-14
37. Marro, M. L., Daniels, D. A., Andrew, D. P., Chapman, T. D., and Gearing, K. L. (2006) In vitro selection of RNA aptamers that block CCL1 chemokine function Biochem. Biophys. Res. Commun. 349, 270-276
38. Long, S. B., Long, M. B., White, R. R., and Sullenger, B. A. (2008) Crystal structure of an RNA aptamer bound to thrombin RNA 14, 2504-2512
39. Ji, X., Sun, H., Zhou, H., Xiang, J., Tang, Y., and Zhao, C. (2011) Research progress of RNA quadruplex Nucleic Acid Ther. 21, 185-200